Trial Profile
An open-label, randomized, 4-period, 4-treatment crossover study to investigate the extent of absorption of Apixaban in different regions of the gastrointestinal (GI) tract
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Apixaban (Primary) ; Apixaban
- Indications Acute coronary syndromes; Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bristol-Myers Squibb; Pfizer
- 04 Apr 2018 New trial record
- 26 Mar 2018 Results published in the Journal of Clinical Pharmacology.